The ADC Wave Continues Throughout 2023
Accelerate Your Antibody-Drug Conjugate Pipeline to
Become a Front-Line Treatment
The ADC momentum has continued to dominate the oncology field throughout 2023, with the long-awaited approval of ImmunoGen’s ELAHERE – the 9th ADC to be approved in just three years. To add to the excitement, this incredible breakthrough is the first ADC for platinum-resistant ovarian cancer, proving their potential for treatments beyond breast cancer.
Whether you have just ventured into the ADC space or are an ADC guru, the 14th World ADC San Diego has got you covered. Accompanying you from early discovery to late-stage manufacturing and regulatory challenges, this meeting has been designed with one aim in mind: to maximize the therapeutic window of your ADC, and propel ADCs to become life-changing, front-line treatments for oncology patients.
Relive the 2022 Event Highlights
With over 800 world-leading ADC experts in attendance including Daiichi Sankyo, ImmunoGen, AbbVie, Gilead Sciences, and Seagen, this is set to be the biggest-ever convergence of the ADC community yet and you cannot afford to miss it!
800+ Attendees & Counting...
End-To-End ADC Development Content for All Members of Your Team
Whether you have just ventured into the ADC space or are an ADC guru, we’ve got you covered.
Your 120 + World Class Speakers Include
Head of Process Quality & CMC Analytical
Senior Principal Scientist
Director Translational Medicine
Proud To Partner With
About World ADC Series
Designed to make sure ADC experts are up to date with industry's advancements, the World ADC Event Series unites 1,500+ experts in the field to provide valuable insights and connections to advance ADCs as a first-option treatment. From globally leading conferences to webinars and industry reports, whatever the information you need, the 14th World ADC San Diego can offer you the insights you need to maximizing the therapeutic window of ADCs and help to bring safe and effective therapies to market faster.